

# ACR–AIUM–SPR–SRU PRACTICE PARAMETER FOR THE PERFORMANCE OF CONTRAST ENHANCED ULTRASOUND

Revised 2023 (Resolution 33)

The American College of Radiology, with more than 30,000 members, is the principal organization of radiologists, radiation oncologists, and clinical medical physicists in the United States. The College is a nonprofit professional society whose primary purposes are to advance the science of radiology, improve radiologic services to the patient, study the socioeconomic aspects of the practice of radiology, and encourage continuing education for radiologists, radiation oncologists, medical physicists, and persons practicing in allied professional fields.

The American College of Radiology will periodically define new practice parameters and technical standards for radiologic practice to help advance the science of radiology and to improve the quality of service to patients throughout the United States. Existing practice parameters and technical standards will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated.

Each practice parameter and technical standard, representing a policy statement by the College, has undergone a thorough consensus process in which it has been subjected to extensive review and approval. The practice parameters and technical standards recognize that the safe and effective use of diagnostic and therapeutic radiology requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published practice parameter and technical standard by those entities not providing these services is not authorized.

## PREAMBLE

This document is an educational tool designed to assist practitioners in providing appropriate radiologic care for patients. Practice Parameters and Technical Standards are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care<sup>1</sup>. For these reasons and those set forth below, the American College of Radiology and our collaborating medical specialty societies caution against the use of these documents in litigation in which the clinical decisions of a practitioner are called into question.

The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by the practitioner considering all the circumstances presented. Thus, an approach that differs from the guidance in this document, standing alone, does not necessarily imply that the approach was below the standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set forth in this document when, in the reasonable judgment of the practitioner, such course of action is indicated by variables such as the condition of the patient, limitations of available resources, or advances in knowledge or technology after publication of this document. However, a practitioner who employs an approach substantially different from the guidance in this document may consider documenting in the patient record information sufficient to explain the approach taken.

The practice of medicine involves the science, and the art of dealing with the prevention, diagnosis, alleviation, and treatment of disease. The variety and complexity of human conditions make it impossible to always reach the most appropriate diagnosis or to predict with certainty a particular response to treatment. Therefore, it should be recognized that adherence to the guidance in this document will not assure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources, and the needs of the patient to deliver effective and safe medical care. The purpose of this document is to assist practitioners in achieving this objective.

---

<sup>1</sup> *Iowa Medical Society and Iowa Society of Anesthesiologists v. Iowa Board of Nursing*, 831 N.W.2d 826 (Iowa 2013) Iowa Supreme Court refuses to find that the "ACR Technical Standard for Management of the Use of Radiation in Fluoroscopic Procedures (Revised 2008)" sets a national standard for who may perform fluoroscopic procedures in light of the standard's stated purpose that ACR standards are educational tools and not intended to establish a legal standard of care. See also, *Stanley v. McCarver*, 63 P.3d 1076 (Ariz. App. 2003) where in a concurring opinion the Court stated that "published standards or guidelines of specialty medical organizations are useful in determining the duty owed or the standard of care applicable in a given situation" even though ACR standards themselves do not establish the standard of care.

## I. INTRODUCTION

The clinical aspects contained in specific sections of this practice parameter (Introduction, Specifications of the Examination, and Equipment Specifications) were developed collaboratively by the American College of Radiology (ACR), the American Institute of Ultrasound in Medicine (AIUM), the Society of Pediatric Radiology (SPR), and the Society of Radiologists in Ultrasound (SRU). Recommendations for Qualifications and Responsibilities of Personnel, Written Requests for the Examination, Documentation, and Quality Control and Improvement, Safety, Infection Control, and Patient Education vary among the three organizations and are addressed by each separately.

## II. INDICATIONS

Indications for contrast enhanced ultrasound (CEUS) are based on the current literature recommendations and clinical practice standards.

Ultrasound (US) contrast agents and contrast-specific scanning techniques have extended the diagnostic capabilities of US. CEUS should be considered as a useful problem-solving tool and as an indicated first-line imaging modality in select settings as indicated below.

US contrast has no renal toxicity or clearance; therefore, CEUS may be used at any level of renal function. CEUS is often safe for patients with contraindications to CT or MRI, including allergies to iodinated and gadolinium-based contrast material, claustrophobia, or immobility. Unlike CT, CEUS uses no ionizing radiation, which makes it particularly advantageous in pediatric patients. Additionally, sedation and/or general anesthesia are not required for patients who cannot comply with immobility or breath-hold instructions, including pediatric patients. CEUS may be performed without screening for incompatible metallic objects such as pacemakers, as is required for MRI.

## II. INDICATIONS

### A. Liver

1. Characterize focal liver lesions in the noncirrhotic adult liver or in the liver of a pediatric patient
  - i. Further characterize incidentally found liver lesions on US
  - ii. Evaluate incompletely characterized lesions on noncontrast or contrast enhanced CT or MRI
2. Characterize focal liver lesions in the cirrhotic liver
  - i. Assess nodules detected on surveillance US
  - ii. Assess LI-RADS (LR): LR-2, LR-3, LR-4, or LR-M observation on prior contrast enhanced CT or MRI
3. Detect arterial phase hyperenhancement when mistiming is suspected as the reason for its absence on prior CT or MRI
4. Detect washout not confidently seen on prior CT or MRI
5. Assess biopsied lesions with inconclusive histology
6. Follow up small observations, or observations not definitive for hepatocellular carcinoma for interval change
7. Detect metastases
8. Evaluate vasculature and portal pressures [\[1-6\]](#)
  - i. Determine hepatic artery, portal vein, and hepatic vein patency
  - ii. Assess transjugular intrahepatic portosystemic shunt patency
  - iii. Distinguish bland thrombus versus tumor in vein
9. Guiding locoregional treatment of lesions that are poorly visualized on grayscale US
10. Assess residual viable disease following ablation or transarterial chemoembolization of hepatic malignancy.
11. Help select appropriate sites for biopsy by improving visualization of target and distinguishing viable (enhancing) from nonviable (nonenhancing) components

## II. INDICATIONS

### B. Kidney and Bladder

1. Intravenous Applications:
  - i. Differentiate between renal tumors and anatomical variants mimicking a renal tumor

- ii. Differentiate cystic and solid renal masses
  - iii. Characterize renal lesions based on complexity of features
  - iv. Follow up nonsurgical renal lesions for change in size or other features
  - v. Follow up for renal cancer recurrence following percutaneous ablation
  - vi. Differentiate enhancing bladder neoplasm from non enhancing hematoma or other debris in patients with hematuria
  - vii. Help select appropriate sites for biopsy by distinguishing viable (enhancing) from nonviable (nonenhancing) components.
  - viii. Identify and guide for drainage of renal abscesses in complicated acute pyelonephritis
  - ix. Improve diagnosis of renal artery stenosis or resolve vascular patency questions
  - x. Assessment of native renal perfusion/cortical necrosis in the setting of acute renal failure
  - xi. Evaluate transplant perfusion: infarct or ischemia
  - xii. Evaluate transplant artery and vein patency
2. Intracavitary Applications:
- i. Pediatric contrast enhanced voiding urosonography
    - Evaluation of prenatally detected hydronephrosis and urinary tract malformations
    - Diagnosis and follow-up vesicoureteral reflux
    - Characterize urethral abnormalities
    - Identification and characterization of urachal anomalies
  - ii. Antegrade nephrostogram for evaluation of ureteral patency in the setting of indwelling nephrostomy tube [7]
  - iii. Evaluate the presence and location of fistulae in anorectal malformations [8]: contrast enhanced genitasonography
3. Vessels
- a. Follow-up of endovascular aortic repair (EVAR) for the detection and classification of endoleaks
  - b. Differentiate between total carotid and vertebral artery occlusion and residual flow through a tight stenosis

## II. INDICATIONS

### C. Pancreas

1. Differentiate vascular (solid) from avascular (eg, liquid or necrotic) components of a pancreatic lesion
2. Follow-up of indeterminate cystic pancreatic lesions
3. Improve the accuracy of percutaneous US-guided pancreatic procedures
4. Evaluate perfusion of pancreas transplant allograft [9]
5. Distinguish acute interstitial pancreatitis from necrotizing pancreatitis [10]

## II. INDICATIONS

### D. Bowel

1. Estimate disease activity in inflammatory bowel disease
2. Monitor the effect of treatment in Crohn's disease
3. Distinguish abscesses from inflammatory mass and improve visualization of fistulous tracks
4. Evaluate infants with suspected necrotizing enterocolitis for nonenhancing bowel

## II. INDICATIONS

### E. Spleen

1. Diagnose splenic infarction
2. Characterize indeterminate splenic lesions [11,12]

## II. INDICATIONS

### F. Scrotum

1. Distinguish vascularized masses from nonvascularized, nontumorous focal testicular lesions
2. Identify testicular infarction

## II. INDICATIONS

### G. Trauma

1. Evaluate for solid organ trauma
2. Evaluate for active bleeding
3. Evaluate for posttraumatic pseudoaneurysms

## II. INDICATIONS

### H. Intracavitary injection

1. Identify needle or confirm catheter position, delineate any cavity or duct, improve tracking of fistulae.
2. Hysterosalpingography for confirming fallopian tube patency [13] [14,15]
3. Evaluate empyema complexity via chest tube injection [16]

## II. INDICATIONS

### I. Interventional guidance [17]

1. Avoid necrotic tissue to improve cytologic yield in the biopsy of tumors
2. Assist in identifying biopsy targets inconspicuous on noncontrast US or noncontrast CT
3. Assess for active bleeding after procedure

## II. INDICATIONS

### J. Other

1. Assess vascularized versus nonvascularized lesions in any other part of the body in addition to the organs listed
2. Intraoperative guidance and identification of resection margin [18]
3. Distinguish necrotic from nonnecrotic lung in pediatric pneumonia [16]
4. Distinguish complex from simple ovarian cysts
5. Distinguish gallbladder inspissated bile (tumefactive sludge) from vascularized soft tissue that may indicate neoplasm or focal adenomyomatosis [10]
6. Improve diagnostic performance of US in infant brain evaluation [19,20]
7. Evaluate neonatal brain hypoxic ischemic injury [21]

## III. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL

See the [ACR–SPR–SRU Practice Parameter for the Performance and Interpretation of Diagnostic Ultrasound Examinations](#) [22].

An additional resource that may be helpful for training requirements is the European Federation of Societies for Ultrasound in Medicine and Biology CEUS Minimum Training Requirements for the Practice of Medical Ultrasound in Europe [23].

Appropriate training and education are strongly advised for every operator who performs CEUS examinations. Furthermore, users should ensure that their US scanning machine is optimized for CEUS acquisition and the

postprocessing of data. The operator must gain sufficient knowledge of indications and contraindications of CEUS and training in US contrast agent (UCA) administration and perform CEUS within the medicolegal framework.

#### **IV. SPECIFICATIONS OF THE EXAMINATION**

The written or electronic request for a contrast enhanced ultrasound examination should provide sufficient information to demonstrate the medical necessity of the examination and allow for its proper performance and interpretation.

Documentation that satisfies medical necessity includes 1) signs and symptoms and/or 2) relevant history (including known diagnoses). The provision of additional information regarding the specific reason for the examination or a provisional diagnosis would be helpful and may at times be needed to allow for the proper performance and interpretation of the examination.

The request for the examination must be originated by a physician or other appropriately licensed health care provider. The accompanying clinical information should be provided by a physician or other appropriately licensed health care provider familiar with the patient's clinical problem or question and consistent with the stated scope of practice requirements. (ACR Resolution 35, adopted in 2006 - revised in 2016, Resolution 12-b)

Depending on a state or institution's interpretation of the CMS rules of participation, a radiologist may add contrast to a "noncontrast" US order, depending on the indication for the study and/or findings identified during a routine US examination. Adding a same-day contrast study may decrease the time to final diagnosis and may decrease costs and harm by reducing unnecessary follow-up CT or MRI examinations [24].

Contrast Dose: In adults, the Food and Drug Administration (FDA) label dose for most abdominal applications is up to 2.4 mL of sulfur hexafluoride lipid microspheres (SHLM) contrast. However, the sensitivity to microbubble US contrast is substantially increased with modern equipment, and using a lower dose of 1–1.5 mL may be required to not saturate the image, limiting diagnostic accuracy. Larger doses may be needed when using high-frequency transducers and when imaging superficial structures or other tissues with low blood volume relative to liver or kidney. The half-life of SHLM contrast is relatively short (5 min), allowing multiple sequential injections. In children, the dose is 0.03 mL/kg up to a maximum of 2.4 mL per injection [25]. Intravascular administration of up to 5 mL of SHLM contrast in a single session is approved by the FDA.

The standard dose of perflutren lipid microspheres (PLM) contrast is 10 µL/kg. The standard dose of perflutren protein microspheres (PPM) contrast is 0.5 mL. Additional 0.5-mL doses may be given to improve characterization of a finding or overcome artifacts encountered during the initial injection.

A 20-gauge (G) or larger venous line should be used to minimize microbubble destruction. Smaller lines may be used

when necessary, particularly in pediatric populations, with the minimum allowable size dependent on the type of microbubble. However, lines below 25G should generally be avoided. A 3-way stopcock attached to the venous line is often beneficial for minimizing time between contrast injection and subsequent saline flush. The contrast dose should be loaded along the straight bore of the stopcock, with a 5 or 10 cc saline syringe attached to the side bore. The rate of contrast injection varies between indications, but is often 1–2 cc/second followed by a 5–10 cc saline flush administered at the same rate [26]. Central venous lines and ports may be used following local and institutional guidelines and policies

#### **IV. SPECIFICATIONS OF THE EXAMINATION**

##### **A. Summary of Scanning Protocols**

##### **1. General abdominal applications [27]**

Most abdominal organs enhance rapidly and intensely 10–15 seconds after US contrast administration. The

arterial vessels enhance first, followed by diffuse parenchymal enhancement. Contrast enhancement usually persists for 4–6 minutes after injection. Unlike CT and MRI contrast agents, microbubbles are not excreted by the kidneys or biliary system. Therefore, no microbubbles are detected in the renal collecting or biliary systems.

- a. Imaging may be performed continuously or intermittently from contrast injection until the imaging target is expected to be completely enhanced (usually 60 seconds).
- b. Thereafter, intermittent imaging (viewing for 3-5 seconds every 30-60 seconds) may be performed to evaluate washout.

#### **IV. SPECIFICATIONS OF THE EXAMINATION**

##### **A. Summary of Scanning Protocols**

##### **2. Liver**

Hepatic imaging protocol is based on the ACR CEUS LI-RADS recommendations.

- a. CEUS of the liver is usually performed to assess targets clearly identified on precontrast B-mode imaging. CEUS may be limited in patients with high body mass index (BMI) and in patients with severe hepatic steatosis, mainly because of substantial US signal attenuation.
- b. Contrast Dose: Contrast dose specified by the manufacturer should be used for the majority of examinations. Imaging of very superficial liver lesions with higher-frequency probes will require contrast dose increase. In addition to patient factors, the contrast dose can be adjusted down based on the sensitivity of the equipment used for CEUS examination [28,29].
- c. Imaging should be performed continuously from contrast injection until peak arterial phase enhancement to characterize the presence, intensity, and pattern of arterial phase enhancement. Alternatively, continuous imaging can be extended beyond peak arterial phase enhancement until 60 seconds after contrast injection to determine the presence of early washout. After 60 seconds, recording of static images should be performed intermittently (3-5 seconds every 30-60 seconds) to detect late washout and to assess its degree. Continuous insonation of large portions of the highly vascular liver may result in excessive destruction of microbubbles, thereby limiting assessment for true washout.
- d. Imaging of multiple nodules often requires more than one contrast injection and careful planning of patient positioning to maximize the use of limited acoustic windows. In patients with multiple liver nodules, two or three nodules can usually be imaged in one session.
- e. The entire liver should be scanned after peak enhancement to detect areas of washout that may represent metastatic lesions.

#### **IV. SPECIFICATIONS OF THE EXAMINATION**

##### **A. Summary of Scanning Protocols**

##### **3. Renal: Because of the highly vascular nature of the kidney, CEUS can be performed with less than the standard dose.**

- a. Imaging may be performed continuously or intermittently from contrast injection. Intermittent imaging (viewing for 3-5 seconds every 30-60 seconds) may be performed to evaluate washout, which is helpful to differentiate pseudo-masses from true neoplasms.
- b. Lesion characterization often requires comparison to adjacent renal parenchyma. Therefore, ensuring a segment of parenchyma is within the field of view during the contrast injection is important for comparison with the target lesion.

#### **IV. SPECIFICATIONS OF THE EXAMINATION**

##### **A. Summary of Scanning Protocols**

##### **4. Other abdominal applications [27]**

#### **IV. SPECIFICATIONS OF THE EXAMINATION**

## A. Summary of Scanning Protocols

### 5. EVAR and vascular

- a. Contrast dose: CEUS examination of the aorta and great vessels is usually performed using a decreased dose of US contrast (ie, 50%-75% of the standard dose [1.5-2.0 mL of SHLM contrast, 0.2 mL of PLM contrast, or 1.0 mL of PPM contrast]) [30].
- b. Imaging:
  - i. Initial CEUS examination should focus on time of enhancement of the aneurysmal sac versus the endograft lumen.
    - a) Contributing vessels can be identified.
  - ii. The examination should continue for at least 10 minutes to ensure that delayed and low-flow endoleaks are identified.

## IV. SPECIFICATIONS OF THE EXAMINATION

### A. Summary of Scanning Protocols

#### 6. Scrotum

- a. Contrast dose: CEUS examination of scrotum is performed with high-frequency transducers, requiring higher doses of contrast (4.8 mL of SHLM contrast, 0.4 mL of PLM contrast, or 2 mL of PPM contrast).
- b. Imaging with linear high-frequency transducers should be performed. CEUS imaging should focus on the arterial phase because it is the most important aspect of the examination. Imaging should be performed continuously from contrast injection until the imaging target is adequately characterized. Presence and degree of arterial phase enhancement should be documented.

## IV. SPECIFICATIONS OF THE EXAMINATION

### A. Summary of Scanning Protocols

#### 7. Neonatal brain [19-21,31]

- a. Contrast dose: CEUS examination of the neonatal brain is performed using the standard pediatric weight-based dose of 0.03 mL/kg SHLM contrast.
- b. Imaging:
  1. CEUS examination of the neonatal brain is performed with a small footprint curved-array mid-frequency transducer.
  2. CEUS is performed by saving cinematic clips.
  3. Once SHLM has been injected, care must be taken to only image in low mechanical index (MI), low TI, and low power output mode to avoid microbubble destruction and potential sonoporation. High MI pulses to clear the field should not be used.
  4. First, a wash-in cinematic clip is obtained in the coronal plane at the level of the third ventricle for 30 seconds after contrast injection. [20]
  5. Second, coronal anterior to posterior cinematic sweeps followed by right-to-left sagittal cinematic sweeps are saved to include both supratentorial and infratentorial structures.
  6. Finally, a cinematic sweep of the posterior fossa through the mastoid fontanelle is saved.
  7. Imaging may require more than one injection to visualize all relevant anatomy and pathology, depending on clinical indication.

## IV. SPECIFICATIONS OF THE EXAMINATION

### A. Summary of Scanning Protocols

#### 8. Pediatric voiding urosonography [32,33]

- a. Contrast dose: To date, published studies have used either SHLM contrast or PPM contrast. The FDA-

recommended contrast dose and administration of SHLM contrast is a 1-mL injection into a bladder that is partially filled with normal saline. However, a suspension of UCA and normal saline can also be infused into the bladder at a dose of approximately 0.2% of bladder filling volume. The optimal contrast dose may vary with the use of different US equipment and should be optimized for image quality.

- b. Imaging: Imaging of the bladder, retrovesical space to assess the distal ureters, and both kidneys is performed in the supine, lateral decubitus, and/or prone position during bladder filling. Multiple cycles of bladder filling and voiding are performed in neonates and infants due to frequent voiding and to increase the rate of detection of reflux. The urethra is imaged from either a suprapubic or transperineal approach during voiding. Studies are documented with static images and cine clips.

#### IV. SPECIFICATIONS OF THE EXAMINATION

##### A. Summary of Scanning Protocols

###### 9. Intracavitary injection

No standard UCA dose or imaging protocol has been established for intracavitary applications. The reported dose range for intravesical injection is 0.1–1.0 mL SHLM contrast, 0.1–0.2 mL of PLM contrast, or 0.1–0.5 mL of PPM contrast diluted in ≈10 mL of 0.9% normal saline. If scanning is performed using high-frequency US transducers, a higher concentration of contrast agent may be required for optimal visualization.

#### IV. SPECIFICATIONS OF THE EXAMINATION

##### A. Summary of Scanning Protocols

###### 10. Interventional guidance [17]

- a. Contrast dose: Recommended dose of UCAs for interventional imaging is 2.4 mL of SHLM contrast, 0.2 mL of PLM contrast, or 1.0 mL of PPM contrast. Similar to other applications, the dose of contrast material could be adjusted based on patient's BMI, depth of the lesion, and transducer frequency.
  - i. When performing interventional CEUS guidance, several injections of US contrast might be required.
  - ii. The first bolus injection can be used to identify the target lesion and plan the procedural approach.
  - iii. The second bolus (or in some cases continuous contrast infusion) can be used to guide biopsy needle placement.
  - iv. When the target lesion begins to clearly appear following the second contrast agent injection (or infusion), the biopsy needle or ablation device is advanced into the target.
- b. Imaging
  - i. In large/partially necrotic tumors, sampling should be performed based on arterial phase hyperenhancement of actively perfused viable tumor components.
  - ii. In smaller lesions poorly seen on routine B-mode US, the biopsy is performed in the late phase of CEUS imaging, targeting areas of tumor washout surrounded by actively perfused normal liver parenchyma.

#### V. DOCUMENTATION

Reporting should be in accordance with the [ACR Practice Parameter for Communication of Diagnostic Imaging Findings \[34\]](#).

Adequate documentation is essential for high-quality patient care. There should be a permanent record of the US examination and its interpretation, including cine clips. Comparison with prior relevant imaging studies may prove helpful. Images of all appropriate areas, both normal and abnormal, should be recorded. Images should be labeled with the patient identification, facility identification, examination date, and image orientation. An official interpretation (final report) of the US examination should be included in the patient's medical record. Retention of the US examination images should be consistent both with clinical need and with relevant legal and local health



care facility requirements.

#### Data storage and access

All relevant images should be properly labeled to include the target and plane of imaging. The report or electronic medical record should include the type of contrast injected, number of injections, route, and dose. The relevant images should be stored digitally on a Picture Archiving and Communication System (PACS). The images should be readily available for review by all physician teams caring for the patient and making medical decisions based upon the results. Image storage should meet all local, state, and federal requirements for medical record document retention. Current and prior studies must be accessible in a reasonable timeframe for the clinical needs of the medical staff and the medical facility. See the [ACR–AAPM–SIIM Technical Standard for Electronic Practice of Medical Imaging \[35\]](#) for further details.

## VI. EQUIPMENT SPECIFICATIONS

Equipment performance monitoring should be in accordance with the [ACR–AAPM Technical Standard for Diagnostic Medical Physics Performance Monitoring of Real Time Ultrasound Equipment \[36\]](#).

The depth of penetration and image clarity may be reduced by low MI imaging. However, using a higher MI can result in microbubble destruction. This generates strong echoes that can produce artifactual or pseudo-washout.

#### Image acquisition

All CEUS studies should be performed on a machine with contrast imaging capability and dual display mode. Each vendor has different proprietary methodology for optimal detection and display of CEUS. Regardless of the vendor, the modality and instrument settings that optimize visualization of contrast and opacification of vascular structures should be employed. Most of these techniques use a real-time low MI technique, usually <0.2 for continuous imaging. A high MI mode may be chosen for rapid bubble destruction in the field of view to evaluate microbubble replenishment. The targeted lesion should be imaged with B-mode before the contrast study.

Contrast agent detection relies upon nonlinear, contrast-specific imaging (most commonly variations of harmonic imaging), and fundamental (nonharmonic) imaging should be avoided. Suppression of background tissue signal by phase/amplitude modulation and harmonic techniques can increase the sensitivity of the machine to CEUS signal, but strongly reflective structures may still create artifact despite background suppression. Likewise, a high doses of contrast may limit visualization of deeper structures; therefore, proper dosing of contrast is important. For example, when evaluating the kidney with contrast, avoidance of a window that contains overlying spleen or liver will improve renal CEUS assessment.

Gain settings should be adjusted to reduce signal from background structures before CEUS injection. Scan plane should be selected to avoid overlying shadowing structures and keep the target lesion in the plane of imaging during quiet respiration. If the focal zone can be manually adjusted, it is typically placed at the deepest portions of the region of concern (organ or lesion). For deeper lesions, lower frequency is preferred for depth penetration and optimized microbubble signal. If higher frequency is selected, an increased volume of contrast may be necessary to achieve adequate contrast enhancement display because the microbubble signal is higher at typical lower transducer frequencies, closer to the microbubble volume resonance frequency. .

## VII. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION

Policies and procedures related to quality, patient education, infection control, and safety should be developed and implemented in accordance with the ACR Policy on Quality Control and Improvement, Safety, Infection Control, and Patient Education appearing under the heading *Position Statement on QC & Improvement, Safety, Infection Control, and Patient Education* on the ACR website (<https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Quality-Control-and-Improvement>).

## VII. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION

## **A. Intravascular administration**

Mild physiologic adverse reactions include nausea and vomiting, taste alteration, headache, vertigo, flushing, and rash. These have an incidence of 0.2% [37-39] and resolve spontaneously without lasting effects.

US contrast agents (UCAs) are safe for patients with compromised renal function or renal obstruction because they are not excreted by the kidneys. No blood tests are needed before administration.

## **VII. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION**

### **A. Intravascular administration**

#### **1. Anaphylactoid (allergic-like) reactions**

UCAs carry an FDA black box [40] warning and are contraindicated in patients with a history of allergy to the agent or its components, such as polyethylene glycol.

Hypersensitivity events are due to anaphylactoid (allergic-like) reactions to the gas or shell. Anaphylactoid reactions include hypotension with tachycardia, bronchospasm, urticaria, and pruritus. The incidence of serious anaphylactoid reactions is 0.006%–0.01% [38,41], which is comparable to gadolinium-based contrast agents and lower than that for iodinated contrast agents. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions. A rate of 0.001% has been reported for life-threatening anaphylactoid reactions, less than the rate for CT or MR contrast agents [42].

In most cases, hypersensitivity events occur within a few minutes of injection. Resuscitation equipment and trained personnel should be available when UCAs are administered. Contrast reactions should be managed according to the [ACR Manual on Contrast Media Version](#) [43] and the [ACR–SPR Practice Parameter for the Use of Intravascular Contrast Media](#) [44].

UCAs have a similar safety profile in children [45-47].

## **VII. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION**

### **A. Intravascular administration**

#### **2. Intravesical and intracavitary administration**

Mild physiologic adverse events during intravesical administration of UCAs in children have been reported in 0.8%–3.8% of cases and are thought to be primarily related to bladder catheterization and not the UCA [48,49].

Intracavitary administration of UCAs has not been associated with specific complications.

## **VII. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION**

### **A. Intravascular administration**

#### **3. Pregnancy**

There have been limited studies of US contrast agents in pregnant patients for SHLM contrast or PLM contrast [50-54]. The limited literature suggests that using CEUS in pregnancy is safe; however, it should be documented that the use of CEUS is needed after a risk/benefit assessment. Animal studies have shown no harm to the fetus at doses of SHLM contrast up to 8–17 times the human dose based on body surface area [40,50]. There are no studies on PPM contrast in pregnant humans, but teratogenic effects have been demonstrated in animal studies. The FDA recommends that PPM contrast be used in pregnancy only if the benefit outweighs the risk [55].

## **VII. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION**

### **A. Intravascular administration**

#### **4. Breastfeeding**

There are no data on the presence of UCAs in human milk, the effects on the breastfed infant, or the effects on milk production. The development and health benefits of breastfeeding should be considered along with the mother's need for UCAs and any potential adverse effects on the breastfed infant from UCAs or from the underlying maternal condition. Milk can be pumped and discarded within 24 hours of contrast administration as a precautionary measure.

### **VII. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION**

#### **A. Intravascular administration**

##### **5. Bioeffects of bubble fragmentation**

US pulses at moderate and high mechanical indices result in substantial microbubble oscillation and fragmentation, which are referred to as stable and inertial cavitation, respectively [56]. This microbubble oscillation can have a range of biological effects under certain conditions, ranging from short-term mild changes in cellular permeability at moderate mechanical indices [57-59] to hemolysis and capillary endothelial injury at higher mechanical indices [60-62]. Early results on using these bioeffects to augment cancer treatments have been reported [63-65]. The magnitude of cavitation is proportional to US amplitude [66] and inversely proportional to frequency.

There have been reports of ventricular arrhythmias in echocardiography following imaging protocols that result in microbubble fragmentation when a high MI is applied [67]. However, no evidence of clinical bioeffects from cavitation during abdominal CEUS have been found in humans at clinically relevant doses of contrast, and no cellular injury has been seen with CEUS performed at the low power setting used in nondestructive imaging. However, given the evidence of bioeffects and that therapeutic applications of microbubbles are used with acoustic parameter ranges that have some overlap with diagnostic imaging parameters, microbubble insonation at moderate and high mechanical indices should be used cautiously. The AIUM recommends that practitioners be aware of the MI used for any study, with an MI of 0.4 as a threshold value for bioeffects [68]:

"Induction of premature ventricular contractions, microvascular leakage with petechiae, glomerular capillary hemorrhage, and local cell killing in mammalian tissue in vivo have been reported and independently confirmed for diagnostic US exposure with a MI above about 0.4 and a gas body contrast agent present in the circulation.

"Although the medical significance of such microscale bioeffects is uncertain, minimizing the potential for such effects represents prudent use of diagnostic US. In general, for imaging with contrast agents at an MI above 0.4, practitioners should use the minimal agent dose, MI, and examination time consistent with efficacious acquisition of diagnostic information."

Thus, MI above 0.4 for clearance pulses should be used sparingly and in accordance with the as low as reasonably achievable (ALARA) principle. Without a clearance pulse, contrast will usually be eliminated spontaneously from the circulation within 15 minutes.

Clinical CEUS should generally be performed with low MI imaging of 0.2 or less.

PPM contrast contains human albumin, a derivative of human blood, and may confer a theoretical risk of viral or prion infection; additionally, it may not be used in patients with religious or ethical objections to the intravascular receipt of human blood products.

### **VII. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION**

#### **A. Intravascular administration**

##### **6. Quality control**

All US devices, including those performing CEUS studies, require annual acceptance testing by a trained, qualified physicist and/or their designees. Routine annual quality control is also recommended. See the [ACR-AAPM](#)

[Technical Standard for Diagnostic Medical Physics Performance Monitoring of Real Time Ultrasound Equipment \[36\]](#) for additional details.

## ACKNOWLEDGEMENTS

This practice parameter was revised according to the process described under the heading *The Process for Developing ACR Practice Parameters and Technical Standards* on the ACR website (<https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards>) by the Committee on Practice Parameters and Technical Standards of the ACR Commissions on Ultrasound and Pediatric Radiology in collaboration with the AIUM, the SPR, and the SRU.

### Writing Committee

Members represent their societies in the initial and final revision of this practice parameter.

#### ACR

Wui K. Chong, MD, Chair

Melanie Caserta, MD

Kassa Darge, MD, PhD

David Fetzer, MD

Helena Gabriel, MD

Joel P. Thompson, MD

#### SPR

Carol Barnewolt, MD

Misun Hwang, MD

Leann Linam, MD

#### AIUM

Richard Barr, MD, PhD, FAIUM, FSRU, FACR

Flemming Forsberg, PhD, FAIUM, FAIMBE

Lori Mankowski Gettle, MD, MBA

Giovanna Ferraioli, MD, FAIUM

#### SRU

Michelle L. Robbin, MD, FAIUM, FSRU, FACR

Judy H. Squires, MD

Committee on Practice Parameters – Ultrasound

(ACR Committee responsible for sponsoring the draft through the process)

Nirvikar Dahiya, MD, FAIUM, FSRU, Chair	Michelle L. Melany, MD, FACR
Helena Gabriel, MD, FACR, Vice Chair	Harriet J. Paltiel, MD
Javad Azadi, MD	Rupinder Penna, MD
Marcela Böhm-Velez, MD, FACR	Kristin L. Rebik, DO
Christopher Fung, MD	Judy H. Squires, MD
Jamie Hui, MD	Joel P. Thompson, MD

Committee on Practice Parameters – Pediatric Radiology

(ACR Committee responsible for sponsoring the draft through the process)

Terry L. Levin, MD, FACR, Chair	Jane Sun Kim, MD
John B. Amodio, MD, FACR	Jessica Kurian, MD
Tara M. Catanzano, MB, BCh	Helen R. Nadel, MD
Harris L. Cohen, MD, FACR	Erica Poletto, MD
Kassa Darge, MD, PhD	Richard B. Towbin, MD, FACR
Dorothy L. Gilbertson-Dahdal, MD	Andrew T. Trout, MD
Lauren P. Golding, MD	Esben S. Vogelius, MD
Adam Goldman-Yassen, MD	Jason Wright, MD

Committee on Practice Parameters – Pediatric Radiology

Safwan S. Halabi, MD

Lauren P. Nicola, MD, Chair, Commission on Ultrasound

Richard A. Barth, MD, FACR, Chair, Commission on Pediatric Radiology

David B. Larson, MD, MBA, FACR, Chair, Commission on Quality and Safety

Mary S. Newell, MD, FACR, Chair, Committee on Practice Parameters and Technical Standards

Comments Reconciliation Committee

Dan Rodgers, MD -CSC Chair

Lori Mankowski Gettle, MD, MBA

Elizabeth Hawk, MD-CSC Co-Chair

Misun Hwang, MD

Carol Barnewolt, MD

Amy L. Kotsenas, MD, FACR

Richard Barr, MD, PhD, FAIUM, FSRU, FACR

David A. Larson, MD

Richard A. Barth, MD, FACR

Paul A. Larson, MD, FACR

Melanie Caserta, MD

Stefanie Lee, MD

Wui K. Chong, MD

Terry L. Levin, MD, FACR

Timothy A. Crummy, MD, MHA, FACR

Leann Linam, MD

Nirvikar Dahiya, MD, FAIUM, FSRU

Mary S. Newell, MD, FACR

Kassa Darge, MD, PhD

Lauren Nicola, MD

Giovanna Ferraioli, MD, FAIUM

Michelle L. Robbin, MD, FAIUM, FSRU, FACR

David Fetzer, MD

Judy H. Squires, MD

Flemming Forsberg, PhD, FAIUM, FAIMBE

Joel P. Thompson, MD

Helena Gabriel, MD, FACR

## REFERENCES

1. Machado P, Gupta I, Fenkel JM, et al. Ultrasound Pressure Estimation for Diagnosing Portal Hypertension in Patients Undergoing Dialysis for Chronic Kidney Disease. *J Ultrasound Med* 2021.
2. Hai Y, Chong W, Eisenbrey JR, Forsberg F. Network Meta-Analysis: Noninvasive Imaging Modalities for Identifying Clinically Significant Portal Hypertension. *Digestive diseases and sciences* 2022;67:3313-26.
3. Forsberg F, Gupta I, Machado P, et al. Contrast-Enhanced Subharmonic Aided Pressure Estimation (SHAPE) using Ultrasound Imaging with a Focus on Identifying Portal Hypertension. *Journal of visualized experiments : JoVE* 2020.
4. Gupta I, Fenkel JM, Eisenbrey JR, et al. A Noninvasive Ultrasound Based Technique to Identify Treatment Responders in Patients with Portal Hypertension. *Academic radiology* 2021;28 Suppl 1:S128-s37.
5. Gupta I, Eisenbrey JR, Machado P, et al. Diagnosing Portal Hypertension with Noninvasive Subharmonic Pressure Estimates from a US Contrast Agent. *Radiology* 2021;298:104-11.
6. Eisenbrey JR, Dave JK, Halldorsdottir VG, et al. Chronic liver disease: noninvasive subharmonic aided pressure estimation of hepatic venous pressure gradient. *Radiology* 2013;268:581-8.
7. Chi T, Usawachintachit M, Mongan J, et al. Feasibility of Antegrade Contrast-enhanced US Nephrostograms to Evaluate Ureteral Patency. *Radiology* 2017;283:273-79.
8. Chow JS, Bellah RD, Darge K, et al. Contrast-enhanced genitosonography and colosonography: emerging alternatives to fluoroscopy. *Pediatr Radiol* 2021;51:2387-95.
9. Swensson J, Hill D, Tirkes T, Fridell J, Patel A. Contrast-Enhanced Ultrasound Versus Doppler Ultrasound for Detection of Early Vascular Complications of Pancreas Grafts. *AJR Am J Roentgenol* 2020;215:1093-97.
10. Franke D, Anupindi SA, Barnewolt CE, et al. Contrast-enhanced ultrasound of the spleen, pancreas and gallbladder in children. *Pediatr Radiol* 2021;51:2229-52.
11. Stang A, Keles H, Hentschke S, et al. Differentiation of benign from malignant focal splenic lesions using sulfur hexafluoride-filled microbubble contrast-enhanced pulse-inversion sonography. *AJR Am J Roentgenol* 2009;193:709-21.
12. Yu X, Yu J, Liang P, Liu F. Real-time contrast-enhanced ultrasound in diagnosing of focal spleen lesions. *Eur J Radiol* 2012;81:430-6.
13. Luciano DE, Exacoustos C, Luciano AA. Contrast ultrasonography for tubal patency. *J Minim Invasive Gynecol* 2014;21:994-8.
14. Grigovich M, Kacharia VS, Bharwani N, Hemingway A, Mijatovic V, Rodgers SK. Evaluating Fallopian Tube Patency: What the Radiologist Needs to Know. *RadioGraphics* 2021;41:1876-18961.
15. Qu E, Zhang M, Ju J, Chen Y, Lin X, Zhang X. Is Hysterosalpingo-Contrast Sonography (HyCoSy) Using Sulfur Hexafluoride Microbubbles (SonoVue) Sufficient for the Assessment of Fallopian Tube Patency? A Systematic Review and Meta-Analysis. *Journal of Ultrasound in Medicine*;n/a.
16. Deganello A, Rafailidis V, Sellars ME, et al. Intravenous and Intracavitary Use of Contrast-Enhanced Ultrasound in the Evaluation and Management of Complicated Pediatric Pneumonia. *J Ultrasound Med* 2017;36:1943-54.
17. Malone CD, Fetzer DT, Monsky WL, et al. Contrast-enhanced US for the Interventional Radiologist: Current and Emerging Applications. *RadioGraphics* 2020;40:562-88.
18. Della Pepa GM, Menna G, Ius T, et al. Contrast enhanced ultrasound (CEUS) applications in neurosurgical and neurological settings – New scenarios for brain and spinal cord ultrasonography. A systematic review. *Clinical Neurology and Neurosurgery* 2020;198:106105.
19. Gumus M, Oommen KC, Squires JH. Contrast-enhanced ultrasound of the neonatal brain. *Pediatr Radiol* 2022;52:837-46.
20. Squires JH, Beluk NH, Lee VK, et al. Feasibility and Safety of Contrast-Enhanced Ultrasound of the Neonatal Brain: A Prospective Study Using MRI as the Reference Standard. *AJR Am J Roentgenol* 2022;218:152-61.
21. Hwang M, Barnewolt CE, Jüngert J, Prada F, Sridharan A, Didier RA. Contrast-enhanced ultrasound of the

- pediatric brain. *Pediatr Radiol* 2021;51:2270-83.
22. American College of Radiology. ACR-SPR-SRU Practice Parameter for the Performance and Interpretation of Diagnostic Ultrasound Examinations. Available at: <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/US-Perf-Interpret.pdf>. Accessed March 30, 2018.
  23. Minimum training requirements for the practice of Medical Ultrasound in Europe. *Ultraschall Med* 2010;31:426-7.
  24. W. Streb J, Tchelepi H, Malhi H, Deurdulian C, Grant E. *Retrospective Analysis of Contrast-enhanced Ultrasonography Effectiveness in Reducing Time to Diagnosis and Imaging-related Expenditures at a Single Large United States County Hospital*; 2018.
  25. Hwang M, Back SJ, Didier RA, et al. Pediatric contrast-enhanced ultrasound: optimization of techniques and dosing. *Pediatr Radiol* 2021;51:2147-60.
  26. Dietrich CF, Averkiou M, Nielsen MB, et al. How to perform Contrast-Enhanced Ultrasound (CEUS). *Ultrasound Int Open* 2018;4:E2-e15.
  27. Sidhu PS, Cantisani V, Dietrich CF, et al. The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Long Version). *Ultraschall Med* 2018;39:e2-e44.
  28. Lyshchik A, Kono Y, Dietrich CF, et al. Contrast-enhanced ultrasound of the liver: technical and lexicon recommendations from the ACR CEUS LI-RADS working group. *Abdom Radiol (NY)* 2018;43:861-79.
  29. Kambadakone AR, Fung A, Gupta RT, et al. LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound. *Abdom Radiol (NY)* 2018;43:56-74.
  30. Gurtler VM, Sommer WH, Meimarakis G, et al. A comparison between contrast-enhanced ultrasound imaging and multislice computed tomography in detecting and classifying endoleaks in the follow-up after endovascular aneurysm repair. *J Vasc Surg* 2013;58:340-5.
  31. Hwang M, Tierradentro-Garcia LO. A concise guide to transtemporal contrast-enhanced ultrasound in children. *Journal of ultrasound* 2022.
  32. Duran C, Beltran VP, Gonzalez A, Gomez C, Riego JD. Contrast-enhanced Voiding Urosonography for Vesicoureteral Reflux Diagnosis in Children. *Radiographics* 2017;37:1854-69.
  33. Paltiel HJ, Rupich RC, Kiruluta HG. Enhanced detection of vesicoureteral reflux in infants and children with use of cyclic voiding cystourethrography. *Radiology* 1992;184:753-5.
  34. American College of Radiology. ACR Practice Parameter for Communication of Diagnostic Imaging Findings. Available at: <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CommunicationDiag.pdf>. Accessed February 7, 2022.
  35. American College of Radiology. ACR-AAPM-SIIM Technical Standard for Electronic Practice of Medical Imaging. Available at: <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/Elec-Practice-MedImag.pdf>. Accessed June 18, 2018.
  36. American College of Radiology. ACR-AAPM Technical Standard for Diagnostic Medical Physics Performance Monitoring of Real Time Ultrasound Equipment. Available at: <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/US-Equip.pdf>. Accessed February 7, 2022.
  37. Piscaglia F, Bolondi L. The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. *Ultrasound Med Biol* 2006;32:1369-75.
  38. Tang C, Fang K, Guo Y, et al. Safety of Sulfur Hexafluoride Microbubbles in Sonography of Abdominal and Superficial Organs: Retrospective Analysis of 30,222 Cases. *J Ultrasound Med* 2017;36:531-38.
  39. Hu C, Feng Y, Huang P, Jin J. Adverse reactions after the use of SonoVue contrast agent: Characteristics and nursing care experience. *Medicine* 2019;98:e17745.
  40. Bracco Diagnostics. Lumason Prescribing Information. Available at: <https://www.drugs.com/pro/lumason.html>.
  41. Wei K, Mulvagh SL, Carson L, et al. The safety of deFinity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses. *J Am Soc Echocardiogr* 2008;21:1202-6.
  42. Piscaglia F, Bolondi L, Italian Society for Ultrasound in M, Biology Study Group on Ultrasound Contrast A. The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. *Ultrasound Med Biol* 2006;32:1369-75.
  43. American College of Radiology. ACR Manual on Contrast Media. Available at: [https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast\\_Media.pdf](https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf). Accessed February 7, 2022.
  44. American College of Radiology. ACR-SPR Practice Parameter for the use of Intravascular Contrast Media.



Available at: <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/IVCM.pdf>. Accessed October 1, 2018.

45. Rosado E, Riccabona M. Off-Label Use of Ultrasound Contrast Agents for Intravenous Applications in Children: Analysis of the Existing Literature. *J Ultrasound Med* 2016;35:487-96.
46. Yusuf GT, Sellars ME, Deganello A, Cosgrove DO, Sidhu PS. Retrospective Analysis of the Safety and Cost Implications of Pediatric Contrast-Enhanced Ultrasound at a Single Center. *AJR Am J Roentgenol* 2017;208:446-52.
47. Riccabona M. Application of a second-generation US contrast agent in infants and children--a European questionnaire-based survey. *Pediatr Radiol* 2012;42:1471-80.
48. Darge K, Papadopoulou F, Ntoulia A, et al. Safety of contrast-enhanced ultrasound in children for non-cardiac applications: a review by the Society for Pediatric Radiology (SPR) and the International Contrast Ultrasound Society (ICUS). *Pediatr Radiol* 2013;43:1063-73.
49. Papadopoulou F, Ntoulia A, Siomou E, Darge K. Contrast-enhanced voiding urosonography with intravesical administration of a second-generation ultrasound contrast agent for diagnosis of vesicoureteral reflux: prospective evaluation of contrast safety in 1,010 children. *Pediatr Radiol* 2014;44:719-28.
50. Schwarze V, Marschner C, Negrão de Figueiredo G, Rübenthaler J, Clevert DA. Single-Center Study: Evaluating the Diagnostic Performance and Safety of Contrast-Enhanced Ultrasound (CEUS) in Pregnant Women to Assess Hepatic Lesions. *Ultraschall Med* 2020;41:29-35.
51. Roberts VH, Lo JO, Salati JA, et al. Quantitative assessment of placental perfusion by contrast-enhanced ultrasound in macaques and human subjects. *American journal of obstetrics and gynecology* 2016;214:369.e1-8.
52. Denbow ML, Welsh AW, Taylor MJ, Blomley MJ, Cosgrove DO, Fisk NM. Twin fetuses: intravascular microbubble US contrast agent administration--early experience. *Radiology* 2000;214:724-8.
53. Ordén MR, Gudmundsson S, Helin HL, Kirkinen P. Intravascular contrast agent in the ultrasonography of ectopic pregnancy. *Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology* 1999;14:348-52.
54. Roberts VHJ, Morgan TK, Bednarek P, et al. Early first trimester uteroplacental flow and the progressive disintegration of spiral artery plugs: new insights from contrast-enhanced ultrasound and tissue histopathology. *Human reproduction (Oxford, England)* 2017;32:2382-93.
55. GE Healthcare. Optison Prescribing Information. Available at: <https://promo.gelifesciences.com/gl/OPTISONIMAGING/howtouse.html>.
56. Haqshenas SR, Ford IJ, Saffari N. Modelling the effect of acoustic waves on nucleation. *J Chem Phys* 2016;145:024315.
57. Hynynen K, McDannold N, Sheikov NA, Jolesz FA, Vykhodtseva N. Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. *Neuroimage* 2005;24:12-20.
58. Karshafian R, Bevan PD, Williams R, Samac S, Burns PN. Sonoporation by ultrasound-activated microbubble contrast agents: effect of acoustic exposure parameters on cell membrane permeability and cell viability. *Ultrasound Med Biol* 2009;35:847-60.
59. Ferrara K, Pollard R, Borden M. Ultrasound microbubble contrast agents: fundamentals and application to gene and drug delivery. *Annu Rev Biomed Eng* 2007;9:415-47.
60. Price RJ, Skyba DM, Kaul S, Skalak TC. Delivery of colloidal particles and red blood cells to tissue through microvessel ruptures created by targeted microbubble destruction with ultrasound. *Circulation* 1998;98:1264-7.
61. Miller DL, Quddus J. Diagnostic ultrasound activation of contrast agent gas bodies induces capillary rupture in mice. *Proc Natl Acad Sci U S A* 2000;97:10179-84.
62. Shigeta K, Itoh K, Ookawara S, Taniguchi N, Omoto K. Endothelial cell injury and platelet aggregation induced by contrast ultrasonography in the rat hepatic sinusoid. *J Ultrasound Med* 2004;23:29-36.
63. Dimcevski G, Kotopoulis S, Bjånes T, et al. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. *Journal of controlled release : official journal of the Controlled Release Society* 2016;243:172-81.
64. Kotopoulis S, Dimcevski G, Gilja OH, Hoem D, Postema M. Treatment of human pancreatic cancer using combined ultrasound, microbubbles, and gemcitabine: a clinical case study. *Medical physics* 2013;40:072902.

65. Eisenbrey JR, Forsberg F, Wessner CE, et al. US-triggered Microbubble Destruction for Augmenting Hepatocellular Carcinoma Response to Transarterial Radioembolization: A Randomized Pilot Clinical Trial. *Radiology* 2021;298:450-57.
66. ter Haar G. Safety and bio-effects of ultrasound contrast agents. *Med Biol Eng Comput* 2009;47:893-900.
67. Chapman S, Windle J, Xie F, McGrain A, Porter TR. Incidence of cardiac arrhythmias with therapeutic versus diagnostic ultrasound and intravenous microbubbles. *J Ultrasound Med* 2005;24:1099-107.
68. American Institute of Ultrasound in Medicine. Statement on Mammalian Biological Effects in Tissues with Naturally Occurring Gas Bodies. Available at: <https://www.aium.org/officialStatements/6>.

\*Practice parameters and technical standards are published annually with an effective date of October 1 in the year in which amended, revised or approved by the ACR Council. For practice parameters and technical standards published before 1999, the effective date was January 1 following the year in which the practice parameter or technical standard was amended, revised, or approved by the ACR Council.

#### Development Chronology for this Practice Parameter

2019 (Resolution 25)

Revised 2023 (Resolution 33)